Meeting
2024 ASCO Gastrointestinal Cancers Symposium
A modified triplet combination of docetaxel, oxaliplatin, and fluorouracil for gastric cancer (GC) with peritoneal carcinomatosis (PC) and inoperable malignant bowel obstruction (MBO): A multi-center, non-randomized, three-cohort, phase II trial (Zhen Jing).
Authors
Jian Xiao
Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
Jian Xiao , Shanshan Li , Xiaohui Zhai , Wanjia Hong , Taiyuan Cao , Xiaoru Lin , Lishuo Shi , Meiyu Hu , Rongqin Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04840264
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr TPS426)
DOI
10.1200/JCO.2024.42.3_suppl.TPS426
Abstract #
TPS426
Poster Bd #
N11
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+ locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.
First Author: Zhi Peng
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).
First Author: Hiroyuki Arai
Poster
2020 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy with docetaxel plus oxaliplatin and S-1 for locally advanced, resectable gastric or gastro-esophageal junction adenocarcinoma: Short-term results from a phase II trial.
First Author: Tomono Kawase